Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Based on the scientific literature, there are several molecular markers which might be used for the prognosis of breast cancer. Possible molecular prognostic markers are: BRCA-1, BRCA-2,
p53
, erbB oncogenes, loss of heterozygosity (LOH), chromosomal aberrations, microsatellite instability,
transforming growth factor alpha
(TGFalpha), and the multiple drug resistance (MDR) gene. In this chapter, we discuss the possible role of these prognostic markers in breast cancer.
...
PMID:Molecular prognostic markers in breast cancer. 1006 82
Previous reports indicate that the expression of
transforming growth factor alpha
(
TGF-alpha
) is increased in enzyme-altered foci (EAF) arising in livers of rats treated with a carcinogen. Here we have investigated the effects of
TGF-alpha
on EAF cells in vitro. Hepatocytes were isolated from rats that had received repeated treatment with diethylnitrosamine (DEN) and whose livers contained glutathione S-transferase P (GST-P)-positive EAF. Primary cultures of GST-P-positive and GST-P-negative hepatocytes were exposed to
TGF-alpha
.
TGF-alpha
(20-40 ng/ml) increased DNA replication in the GST-P-negative, but not in the GST-P-positive cells. Furthermore, it was shown that this effect on GSTP-negative cells could be blocked by
p53
antisense oligonucleotides. We conclude that EAF hepatocytes do not respond to
TGF-alpha
in vitro. This lack of response may reflect the attenuated expression of
p53
in these cells. These data corroborate previous findings that, in response to DNA damage, many EAF hepatocytes do not accumulate
p53
.
...
PMID:p53 expression and TGF-alpha-induced replication of hepatocytes isolated from rats exposed to the carcinogen diethylnitrosamine. 1019 48
Previously, transgenic mice were generated that overexpressed v-Ha-ras or human
transforming growth factor alpha
(TGFalpha) exclusively in the epidermis, by means of a targeting vector based on the human keratin 1 gene (HK1). Both transgenics exhibited a similar neonatal phenotype of epidermal hyperplasia/hyperkeratosis and, in adults, spontaneous and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced papilloma formation. To assess the synergism in vivo between Ha-ras and TGFalpha, mating experiments were performed. All ras/TGFalpha double genotype progeny (HK1 less than, with dotras/alpha) exhibited an increased epidermal hyperplasia/hyperkeratosis in neonates and accelerated spontaneous papillomatogenesis, compared with single transgenic siblings. HK1 less than, with dotras/alpha mice from the mild lines of HK1 less than, with dotrasxHK1 less than, with dotTGFalpha developed spontaneous papillomas that were not shown in either their parental mice or single transgenic littermates. Unlika in parental or single-genotype siblings, in which TPA promotion-elicited papillomas remained benign, TPA promotion elicited autonomous papillomas in HK1 less than, with dotras/alpha mice and exhibited a novel susceptibility to malignant conversion. Sequence analysis of the endogenous c-Ha-ras from spontaneous and TPA-induced HK1 less than, with dotras/alpha papillomas revealed wild-type sequence. However, carcinomas exhibited c-Ha-ras mutations at codon 61. All tumors analyzed to date expressed wild-type
p53
. These data provide in vivo evidence that Ha-ras and TGFalpha cooperate in the induction of epidermal hyperplasia and spontaneous tumor formation and predispose to malignant conversion via endogenous c-Ha-ras activation.
...
PMID:Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation. 1070 82
The incidence of gastro-oesophageal junction (GEJ) adenocarcinoma is increasing in Western countries and prognosis is poor since metastasis is most often present at diagnosis. We examined samples from 87 resected type II GEJ adenocarcinomas, 30 of these with endoscopic diagnostic biopsy material, to evaluate
transforming growth factor alpha
(TGF-a) expression and
p53
overexpression by immunohistochemistry and in situ hybridization (for TGF-alpha), in relation to biological and clinical behaviour. TGF-alpha messenger RNA (mRNA) and protein were detectable in neoplastic cells in 56% and 64% cases respectively. TGF-alpha mRNA was detected in intra- and peritumoral lymphocytes and those of metastatic lymph nodes. TGF-alpha protein expression was significantly associated with tumour progression (P= 0.025) and lymph node metastasis (P < 0.05). The strong TGF-alpha expression found in neoplastic cells inside blood and lymphatic vessels and in metastatic localizations suggests that TGF-a-positive GEJ adenocarcinomas could have a more aggressive biological phenotype. The expression of TGF-alpha mRNA and protein in both inflammatory and neoplastic cells indicates that TGF-alpha is directly synthesized by both cell compartments. Finally, since TGF-alpha expression was associated with lymph node metastasis, its detection in preoperative perendoscopic biopsies might identify patients with more aggressive tumours who may need additional therapy, including neo-adjuvant treatment.
...
PMID:Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction. 1073 60
To investigate the role of loss of the
p53 tumor suppressor
gene in skin carcinogenesis,
p53
knockout (
p53
(-/-)) mice were mated with transgenic mice coexpressing v-Ha-ras, v-fos, or human
transforming growth factor alpha
(TGFalpha) exclusively in the epidermis by using human keratin 1 (HK1)-based vectors (HK1.ras/fos, HK1.ras/alpha, and HK1.fos/alpha). HK1.ras/fos and HK1.ras/alpha mice displayed epidermal hyperplasia and autonomous benign papillomas to an identical degree between
p53
(+/+) and
p53
(+/-) genotypes. However, HK1.ras/fos mice with the
p53
(-/-) genotype were born with papillomatous skin and died soon after birth. HK1.ras/alpha-
p53
(-/-) mice also exhibited an increased epidermal hyperplasia, and, similar to HK1.ras/alpha mice with
p53
(+/+) and
p53
(+/-) genotypes, these mice rapidly developed spontaneous and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced papillomas. These results are in contrast to our previous observation that, HK1.ras, HK1.fos, and HK1.TGFalpha transgenic mice with the
p53
(-/-) genotype display an unexpected delay in both spontaneous and TPA-promoted papilloma formation compared with mice with
p53
(+/+) and
p53
(+/-) genotypes. Taken collectively, our mating experiments between HK1 oncogenic transgenic mice and
p53
knockout mice may identify a backup system that effectively compensates for
p53
loss. Activation of multiple oncogenes not only partly overcomes such compensation but also synergizes with
p53
loss. However, HK1.fos/alpha-
p53
(-/-) mice failed to exhibit either an increased newborn epidermal hyperplasia or an accelerated spontaneous or TPA-induced papillomas, suggesting that certain combinations of oncogenes, such as with activated Ha-ras, are required for this process. Because neither spontaneous nor TPA-elicited papillomas in
p53
(-/-) mice progressed to malignancy, additional genetic insults appear to be required for malignant progression.
...
PMID:Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. 1107 3
Our previous studies have shown that overexpression of aromatase results in increased tissue estrogenic activity and induction of hyperplastic and dysplastic lesions in aromatase transgenic mammary glands. In this study, we have examined the effects of aromatase overexpression on biochemical changes in the aromatase transgenic mice. Our results show an increase in the expression of both estrogen and progesterone receptors, and their expression is maintained in the transgenic mammary tissue even without circulating ovarian estrogens. Our results also show an increase in the expression of several growth factors and cell cycle genes in the aromatase transgenic mammary glands, which is consistent with the observed increase in proliferating cell nuclear antigen levels and cellular proliferation. Interestingly, we have also observed a decrease in the expression of epidermal growth factor receptor and its ligands, epidermal growth factor and
transforming growth factor alpha
, as well as several tumor suppressor genes such as
p53
and retinoblastoma. This study presents novel and interesting findings that are consistent with the current models of aromatase influence and the complex interactions of biochemical pathways leading to mammary tumorigenesis.
...
PMID:Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. 1128 Jul 46
Immunohistochemical analysis of the expression of
transforming growth factor alpha
(
TGF-alpha
) and its receptor, epidermal growth factor receptor (EGFR), was performed in a series of 86 invasive carcinomas of the breast.
TGF-alpha
immunostaining was observed in the majority of the cases (72.1%), both in epithelial cells and in adjacent stromal cells. EGFR was also present in tumors (34.2%) and in the endothelial cells (46.1% of the cases) near the tumors. A significant association was observed between
TGF-alpha
expression and angiogenesis evaluated by immunohistochemistry using an antibody against factor VIII-related antigen. No association was observed between
TGF-alpha
expression and other clinicopathologic features. In contrast, EGFR expression in the tumor was associated with features of poor prognosis, such as tumor size, histologic grade, lymph node status, estrogen receptor content,
p53
expression, sialyl-Tn expression, and age. The presence of EGFR in endothelial cells was correlated to young patient age. We also observed an association of EGFR in endothelial cells and angiogenesis in tumors with a size of less than 2 cm. Inversely, in larger tumors, angiogenesis was only associated with tumor
TGF-alpha
expression. These results indicate that endothelial EGFR may play a role in the early steps of breast cancer angiogenesis.
...
PMID:Expression of TGF-alpha and EGFR in Breast Cancer and its Relation to Angiogenesis. 1134 60
We used a murine tumor progression model for the evaluation of potential proliferation markers using positron emission tomography (PET). 5-[(18)F]-2'-deoxyuridine ([(18)F]FdUrd) was synthesized with >98% radiochemical purity and investigated in a pancreatic cancer model,
transforming growth factor alpha
transgenic mice crossbred to
p53
deficient mice. Thymidylate synthase was increased already in premalignant lesions, whereas thymidine kinase 1 mRNA levels were up-regulated 4-fold in the pancreatic cancer specimen of these mice. PET imaging was performed after injection of 1 MBq of [(18)F]FdUrd and 1 MBq of [(18)F]fluoro-deoxyglucose. Animals with pancreatic cancer displayed focal uptake of both tracers. The [(18)F]FdUrd uptake ratio closely correlated with the proliferation index as evaluated in morphometric and fluorescence-activated cell sorter analysis. These results indicate the potential of our tumor model for the evaluation of PET tracers and suggest [(18)F]FdUrd as a tracer for the assessment of proliferation in vivo.
...
PMID:In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. 1135 95
The tumour suppressor protein,
p53
, is involved in the regulation of apoptosis and growth arrest following DNA damage. Mutations of the
p53
gene are found in 50-55% of all human cancers (Hollstein et al. Nucl. Acid Res. 22 (1994) 3551), including hepatocellular carcinomas. Phenobarbitone (PB) is a non-genotoxic hepatocarcinogen in rats and mice. With commercial availability of mice where one or both alleles of
p53
have been removed we have examined the effect of PB in wild type C57BL/6J mice (
p53
+/+), and
p53
deficient mice (+/- and -/-
p53
) to determine whether
p53
plays a role in the PB induced liver response. In each strain of mice, chronic administration caused liver enlargement, which was associated with centrilobular hepatocyte hypertrophy and a transient hyperplasia. In addition, an increase in centrilobular epidermal growth factor receptor and its ligand,
transforming growth factor alpha
and a decrease in mannose-6-phosphate receptor and its mitoinhibitory ligand, TGFbeta1 was also observed immunohistochemically. The similar response in all three strains indicates that
p53
probably plays no role in the early PB induced liver effects of hypertrophy and changes in growth factor expression.
...
PMID:Phenobarbitone-induced liver response in wild type and in p53 deficient mice. 1143 19
Epithelial tumors of the pancreas exhibit a wide spectrum of histologies with varying propensities for metastasis and tissue invasion. The histogenic relationship among these tumor types is not well established; moreover, the specific role of genetic lesions in the progression of these malignancies is largely undefined. Transgenic mice with ectopic expression of
transforming growth factor alpha
(
TGF-alpha
) in the pancreatic acinar cells develop tubular metaplasia, a potential premalignant lesion of the pancreatic ductal epithelium. To evaluate the cooperative interactions between
TGF-alpha
and signature mutations in pancreatic tumor genesis and progression, TGFalpha transgenic mice were crossed onto Ink4a/Arf and/or
p53
mutant backgrounds. These compound mutant mice developed a novel pancreatic neoplasm, serous cystadenoma (SCA), presenting as large epithelial tumors bearing conspicuous gross and histological resemblances to their human counterpart. TGFalpha animals heterozygous for both the Ink4a/Arf and the
p53
mutation showed a dramatically increased incidence of SCA, indicating synergistic interaction of these alleles. Inactivation of p16(Ink4a) by loss of heterozygosity, intragenic mutation, or promoter hypermethylation was a common feature in these SCAs, and correspondingly, none of the tumors expressed wild-type p16(Ink4a). All tumors sustained loss of
p53
or Arf, generally in a mutually exclusive fashion. The tumor incidence data and molecular profiles establish a pathogenic role for the dual inactivation of p16(Ink4a) and p19(Arf)-
p53
in the development of SCA in mice, demonstrating that p16(Ink4a) is a murine tumor suppressor. This genetically defined model provides insights into the molecular pathogenesis of SCA and serves as a platform for dissection of cell-specific programs of epithelial tumor suppression.
...
PMID:Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. 1175 58
<< Previous
1
2
3
4
5
Next >>